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ABSTRACT 
 
Indolicidin (indol) is a cationic antimicrobial peptide that is isolated from the 
cytoplasmic granules of bovine neutrophils. Known primarily for its high 
percentage of tryptophan residues, indol is of particular interest due to its broad 
spectrum of antimicrobial activity.  While there is currently a lot of information 
available on the minimum inhibitory concentration for indol, as well as for its 
overall spectrum of activity, there remains a gap in knowledge about the mechanism 
of action and a binding constant (Kb) has not yet been reported for its interaction 
with its proposed receptor- lipopolysaccharide (LPS).   This thesis focuses on 
investigating capillary electrophoresis (CE) methods for studying the interaction of 
indol with LPS at physiological pH with the ultimate goal of generating a Kb.   
In Chapter 2, the effect of incubation time is explored using pre-incubation CE.  The 
findings indicate a slow equilibrium that is established at upwards of six hours.  Kb 
values of decreasing magnitude are generated at 2, 5.5 and 10 h (± 0.5) incubation 
times, each data set indicated that formation of the complex is favoured and 
multiple binding stoichiometries are likely present.     
Chapter 3 outlines optimized affinity CE parameters with indol as a constant 
concentration sample and LPS added to the background electrolyte.  A molecular 
mass range is assumed for LPS to produce a conservative Kb range for the 
interaction of indol and LPS.  The results agreed with those of Chapter 2, suggesting 
multiple binding sites and that complex formation is favoured.  Finally, attempted 
use of the frontal analysis CE (FACE) method is described in Chapter 4, outlining 
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optimized parameters and suggestions for successful use of the FACE method. 
Combined, Chapters 2, 3 and 4 set the groundwork for a confident Kb to be reported 
for the interaction of indol with LPS.  Additionally, those methods will translate 
nicely to the study of indol or its derivatives with mammalian cells in future work.   
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CHAPTER 1: INTRODUCTION 
 
The constant overuse and misuse of antibiotics, especially with livestock, has 
accelerated the emergence of antibiotic resistant bacteria and has made the search 
for alternative treatments much more urgent (1).  The search for new viable drugs 
has been extensive for many decades with natural products being at the forefront of 
the drug discovery and development process (2).   Combinatorial libraries, which 
became popular in the 1990s, did not yield the expected surge in productivity and 
focus has returned to research with a basis in natural products.  Research 
surrounding drug receptors and binding is important for drug advancement.  The 
information about indolicidin (indol), lipopolysaccharide (LPS) and capillary 
electrophoresis (CE) to follow is not meant to be exhaustive, but should provide 
some insight for readers whose expertise lie elsewhere.   
 
Indolicidin 
 
From the search for alternative therapeutic agents came a family of drugs known as 
antimicrobial peptides (AMPs). Many living organisms, including plants, animals, 
bacteria and fungi, produce AMPs for defense against invading pathogens (3). They 
employ multiple modes of action against their targets, making them effective against 
many pathogen strains and render them less likely to themselves become drugs to 
which microbes develop resistance (4).  Small, cationic amphiphilic peptides are 
being studied as a novel class of antimicrobials and those used as topical antibiotics 
have progressed to phase III of clinical trials (5). Indolicidin (indol) is a cationic AMP 
that is isolated from bovine neutrophils (6).  It has antibiotic properties against 
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Gram-positive and Gram-negative bacteria, and exhibits activity against protozoa, 
HIV, fungi, and neoplastic cells (6-8). Indol is composed of 13 amino acids, is one of 
the shortest known naturally-occurring AMPs and is renowned for its high 
percentage of tryptophan (38%) and disordered structure (6, 9-11) (Figure 1.1). 
 
 
Figure 1.1: Structure for the antimicrobial peptide Indolicidin.  
 
The peptide also has proline and arginine residues which prevent secondary 
structure from forming and provide the cationic nature, respectively (9, 11).  The rich 
quantity of tryptophan residues and the two WPW (tryptophan, proline, 
tryptophan) motifs present in the indol structure are thought to be responsible for 
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much of its antimicrobial activity (10, 12). At physiological pH, indol has a charge of 
+4 and is thought to enter the cell through defects that it creates in the membrane in 
addition to several other proposed mechanism briefly described later(6). 
Despite its antimicrobial properties, indol is impractical in its current, unaltered 
form due to its toxicity to both prokaryotes and eukaryotes (10, 12). To overcome 
this, many mutants of indol have been created that render it less hemolytic while 
simultaneously increasing its antimicrobial properties (13-15).  In one study, by way 
of solid phase peptide synthesis, five indol derivatives were formed by 
incrementally substituting the very hydrophobic tryptophans with the mildly 
hydrophobic alanines (13).  For the derivative known as Δ45, only the 4th and 5th 
tryptophans in the peptide sequence were substituted, allowing one of the WPW 
motifs to remain intact. This derivative showed the greatest promise.  Further 
research and development of AMPs such as Δ45 could be a step towards a class of 
drugs that are highly effective against many pathogens, with the prospect of 
remaining functional over time.  Additionally, combination studies blending indol 
and other therapeutic agents have shown increased antimicrobial action (16).  
 
Much is known about the properties and interactions of indol:  It has the ability to 
cause membrane-thinning by disruption of headgroups, it adopts different 
equilibrium conformations in solution, and it shows bactericidal action against the 
typically antibiotic resistant Pseudomonas aeruginosa- a ubiquitous, problematic, and 
opportunistic pathogen (16-18).  The precise mechanism of bacterial cell attack is not 
confirmed, but many have been suggested. They include inhibition of protein and 
DNA synthesis, cell leakage via channel formation across the membrane, pore and 
non-pore forming mechanisms among others (17, 19-23). The development of a drug 
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prospect that attacks only cell membranes would be problematic as it would not 
possess the specificity required to single out pathogens while leaving human cells 
intact.  It is for this reason that the multiple modes of attack available to AMPs such 
as indol are of such value.  In studies of antibiotic resistance, Gram-negative bacteria  
are the more abundant source of antibiotic resistance genes and are responsible for 
more costs and resources in the care of hospital patients (24, 25).  It is for this reason 
that drug research surrounding Gram-negative bacteria often trumps that of its 
Gram-positive counterpart.  An important part of continued research involves a 
specific study of the interaction of indol with LPS- its proposed corresponding 
receptor in Gram-negative bacteria (22).   Once studies have been conducted 
between indol and LPS, it is then simply a matter of reproducing similar studies 
with lipoteichoic acid- the LPS equivalent in Gram-positive bacteria in order to 
expand the findings to both types of pathogenic bacteria (26). 
 
Lipopolysaccharide 
 
The complex structure of the Gram-negative cell envelope contains LPS in its outer 
membrane, a component that is absent in the composition of Gram-positive bacteria 
(Figure 1.2).  The role of the outer membrane is to act as a barrier between the 
cytoplasm of the cell and the environment. LPS, a large component of Gram-
negative outer membranes, has the amphipathic properties of phospholipids and 
serves several functions.  Of utmost importance is its role in semi-permeability, only 
allowing passage of low molecular weight and hydrophilic molecules (27).  The LPS 
structure can be broken into three parts: lipid, core and O-antigen (Figure 1.3) (27, 
28).  The lipid portion is generally referred to as “lipid A”.  It consists of a 
phosphorylated N-acetylglucosamine dimer attached to six or seven saturated fatty 
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acids. It is hydrophobic and serves to anchor LPS to the membrane.  The lipid A 
portion of the molecule is responsible for LPS’s toxic properties (28). The core 
portion is also known as the “R-polysaccharide” or “core oligosaccharide”.  The core 
consists of a chain of sugars.  The 2-keto-3-deoxyoctonoic acid is a sugar that is so 
unique to LPS that it can be used in LPS assays.   Unlike the structure of Lipid A, 
which is highly conserved among Gram-negative bacteria, the core polysaccharide 
structure of LPS varies among bacterial genera.  Lastly, the O-antigen region is made 
up of up to 40 repeating 3 - 5 sugar subunits.  This portion of the LPS molecule is the 
biggest, is hydrophilic and the sugars involved are very unique and can even vary 
within a species (27). 
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Figure 1.2: Structure of the cell envelope of Gram-negative bacteria. This figure 
created with guidance from (27). 
  
 As previously described, the actual structure of an LPS unit can vary quite 
substantially from one species to another and even within a species of 
bacteria.  Knowing the precise structure of any commercially acquired sample of 
LPS is difficult as preparations are heterogeneous.  In addition, the LPS units are 
likely to exist in micellar solution when dissolved in solvent, presenting a further 
challenge.  As a single LPS unit, the mass range is approximated at 10-20 kDa 
(28).  In aggregate form, the average mass can be upwards of 1000-4000 kDa.  For 
Sigma Aldrich LPS from E. coli 0111:B4 (used herein), micelles are said to form 
anytime the sample is dissolved in solvent; thus individual LPS units are unlikely to 
be present during analyses (29).  Further research into the critical micelle 
concentration (CMC) of LPS has found that for the E. coli 0111:B4 strain acquired 
from Sigma-Aldrich, the CMC is 1.3- 1.6 µM and aggregates of 43- 49 molecules per 
micelles are formed (30). Using a conservative mass estimate of 10-20 kDa per LPS 
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unit, that places the aggregate mass range at 430- 980 kDa. 
 
 
Figure 1.3: General structure of lipopolysaccharide.  Reference (26) used to 
develop this figure. 
 
To study the mechanism of action of indol with LPS, use of intact bacterial cells 
would be of the greatest benefit for studying the interaction of a prospective drug 
with its target, however, published studies of this nature are few (5).  The 
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permissions involved and measures required to prevent and mitigate possible 
biohazards are likely reasons for avoiding their use.  Simplifying an interaction 
study to only include a drug (indol) and one individual receptor (LPS) disregards 
many important biological features including membrane potential, pH gradients, 
lipid heterogeneity, and the presence of membrane proteins (5).  To reach a broad 
understanding of interaction mechanisms, it is accepted that the simplified 
perspective is still helpful.  Consequently, once the drug receptor is known, it is 
used as an analogue to shed light on the interaction.  In this particular case, LPS is 
used to better understand the binding action of indol and its subsequent entry into 
the cell.   
 
Capillary Electrophoresis 
 
Capillary electrophoresis (CE), also termed High Performance Capillary 
Electrophoresis (HPCE), encompasses a family of methods for the separation of 
molecules based on their movement within a small bore capillary (inner diameter of 
~25-100µm) under an applied electric field (31).  The modes of CE extend to micellar 
electrokinetic capillary chromatography (MECC), capillary gel electrophoresis 
(CGE), and capillary isoelectric focusing (CIEF); however, the simple term “CE” 
usually refers to Capillary Zone Electrophoresis (CZE) whereby separation occurs 
solely by electrophoretic mobility (32).  CE is a young technique when compared to 
High Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC).  
In 1967, Hjertén offered a thesis describing an apparatus for free zone 
electrophoresis in a revolving tube. His thesis was thought to be the direct 
forerunner of modern CZE (33, 34).  The evolution of CE has since flourished and CE 
related publications have grown exponentially.  CE techniques have been applied to 
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genetics, sequencing of nucleic acids and proteins, studies of diseases, the 
identification of species and individuals, analysis of complex matrices, separation of 
very similar molecules (ie., enantiomers and molecules with identical 
physicochemical properties), binding studies of analytes with ligands, protein 
conformations and more (11, 33-37).  CE is a popular technique due to its high 
separation efficiency, automation ability, high resolving power, quick analysis time, 
ability to operate at near physiological pH, and low injection volume resulting in 
comparatively low operational costs (35, 38).   
Binding constants are of great interest in studies of noncovalent molecular 
interactions (36).  The human body alone offers an unlimited number of examples of 
intricate and complex biological processes.  Understanding these processes is aided 
by the elucidation of a binding constant (Kb), also referred to as an equilibrium 
constant, which denotes the relationship between a receptor (R) and a ligand (L), or 
respectfully, a protein (P) and a drug (D) (39).   
For the equilibrium equation 
P + D ⇌ PD           (Eq. 1) 
 
The relationship of free protein (P) and (D) to complex (PD) can be expressed by the 
equation where K=Kb (40):     
  
    
      
          (Eq. 2) 
 
And the ratio (r) of complexed P to total P can be expressed as: 
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       (Eq. 3) 
 
When multiple equilibria are considered, a more complex equation is required  
(41, 42): 
 
  ̅    ∑
         
         
   
            (Eq. 4) 
 
 ̅ is the mean number of moles of D bound per mole of P, 
     is the free ligand concentration, 
   is the number of independent sites of class i, 
    is the association constant with D, and 
 m is the total number of classes. 
 
In the past, methods such as ultracentrifugation, equilibrium dialysis, 
radioimmunoassay, nuclear magnetic resonance , fluorescence quenching and slab 
gel have been used for estimating drug-protein interactions (43).  In the last 20 years, 
CE has become a popular instrument to study the extent of binding and dissociation 
of formed complexes.   Binding studies and the elucidation of a Kb are essential for 
drug development because pharmacological activity is best correlated to the 
concentration of unbound drug (36). There are a variety of CE techniques for the 
study of a Kb that are closely related.  These methods can be subdivided by the way 
the binding parameters are determined.  The Affinity CE (ACE), Vacancy Affinity 
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CE (VACE) and Partial Filling Affinity CE (PFACE) methods measure the change in 
mobility of the species (44).  The Hummel-Dreyer method (HD), Vacancy peak (VP), 
and Frontal Analysis (FA)/Frontal Analysis Continuous CE (FACCE) methods use 
peak area or plateau height to determine the Kb.  Close inspection of each of these 
CE methods, coupled with pilot projects of preliminary outcomes have indicated 
that FACE, ACE and the closely related pre-incubated ACE method, are most 
suitable for studying the interaction of indol with LPS.  These methods are discussed 
in greater detail. 
 
Affinity Capillary Electrophoresis 
 
ACE is the most commonly used CE technique for the study of protein-drug 
interactions with roughly 1000 publications on the subject of ACE between 2000- 
2012 (45, 46). Use of micelles and cyclodextrins, forms of secondary equilibrium, can 
be considered affinity interactions, however, the term ACE is reserved for studies of 
noncovalent interactions of biomolecules with different reagents and is at times used 
as a general term to encompass CE binding studies (33).  Capillary wall coatings are 
commonly used to reduce protein adsorption and improve CE performance (47). 
Contrarily, it has also been suggested that use of precise rinse protocols can 
adequately reduce the extent of protein adsorption and produce usable findings 
with bare fused silica capillaries (48). 
The ACE method of studying affinity interaction has the same experimental setup as 
the HD method.  The difference between the methods is in analysis of the resulting 
electropherogram.  While the HD method uses peak area to calculate the 
equilibrium constant, ACE uses the change in mobility of the injected species (38).  
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Addition of a neutral marker (e.g. DMSO, mesityl oxide, acetonitrile) serves to 
indicate the electroosmotic flow (EOF).  The calculations of Kb are based on the 
electrophoretic mobility of free and complexed drug.   For an assumed 1:1 binding of 
D to P, the electrophoretic mobility (µ) of D is as follows (36, 49):  
    
    
         
   
    
         
         (Eq. 5) 
 
where µi is the apparent  electrophoretic mobility of D,  µf is the mobility of free 
drug (Df), and µc is the mobility of the DP complex.  Eq. 5 can be rearranged as 
follows: 
 
    
    
       (
     
     
)       (Eq. 6) 
 
When employing Eq. (6), µc must be determined experimentally but since the small 
molecular mass of the bound drug is not likely to significantly change the mobility 
of P, it is assumed that µc  µp (36). Knowing the true mobility of the complex is 
almost impossible.  From Eqs. 2 and 5, we obtain (36, 49): 
 
   
          
       
         (Eq. 7) 
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Further rearrangement of Eq. 8 results in:  
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                                             (Eq. 11) 
 
The ACE experimental design requires monitoring the change of the migration time 
for the complexed species (tc) compared with the marker (tm) which indicates a 
change in the electrophoretic mobility (µi) of the complex (44). Voltage (V) used, 
total capillary length (Lt), and the effective length of the capillary (to the detector) 
(Ld) are also important parameters for the determination of µi as follows: 
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The presence of additive in the background electrolyte (BGE) can introduce 
differences in viscosity as increasing concentrations are added (50). A correction can 
be made to Eq. 12 to account for the viscosity effect.  The effective electrophoretic 
mobility µeff is multiplied by the ratio (Io/I), where Io is the current without any 
additives in the buffer solution and I is the current when there is additive in the 
buffer solution.   The corrected µeff are then used to determine Kb based on the 
plotting forms shown in Table 1.1. 
 
Each of the plotting methods listed in Table 1.1 best depicts interactions with a 1:1 
stoichiometry and linearity of those plots helps to support the assumption of 1:1 
binding.  Where multiple binding sites are present, non-linearity is best indicated by 
the X-reciprocal plot (36). Complicated stoichiometries can sometimes be 
determined by identifying more than one trend on an X-reciprocal plot (51, 52). 
Elucidation of the correct stoichiometries may require use of different 
instrumentation (e.g. NMR, UV spectra and MS) (36, 46).  
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Table 1.1: Plotting forms of binding constant (Kb).  
Method  
(synonymous names) 
Plotting Equation  
(y axis  vs x axis) 
Determination 
of Kb 
Equation 
Nonlinear regression 
(mobility ratio difference) 
 
     
     
 vs      slope (6) 
X-Reciprocal  
(Eadie plot,  
Scatchard plot) 
 
       
    
 vs (     ) -slope (11) 
 
Y-Reciprocal 
 
    
       
vs      
     
         
 (10) 
Double-reciprocal 
(Lineweaver–Burk plot,  
Benesi–Hildebrand plot) 
 
 
       
 vs 
 
    
 
         
     
 (9) 
µf, µc and µi are final/free drug, DP complex and apparent electrophoretic mobilities, 
respectively.       is the free protein concentration. Table compiled from (36, 49, 53). 
 
From a generated plot, the resulting Kb value is typically given in (L·mol -1) (54-56). In 
some cases where the molecular mass of the protein or drug is not precisely known, 
the Kb is at times represented in (g/mL)-1 , however this notation makes it very 
difficult to compare and assess relative binding strength (57).  In cases where the 
binding kinetics are deemed to be slow, a modified ACE protocol whereby the drug 
and the protein are pre-incubated prior to CE analysis is appropriate (58).   
 
Pre-incubation Affinity Capillary Electrophoresis (PI-ACE) 
 
The experimental design of the PI-ACE method is almost identical to that of ACE, 
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and the treatment of the resulting data is the same.  Rather than the addition of one 
component to the BGE, both the P and the D are pre-incubated for a set amount of 
time before CE analysis. A viscosity correction (Io/I) that accounts for the change in 
current due to change in BGE is not needed because run buffer and thus current 
remains unchanged. The µeff simply becomes µc -µf and all the same plotting forms 
depicted in Table 1.1 apply. The PI-ACE method is of interest for the investigation of 
the indol-LPS binding because it is well suited for studying slow binding kinetics.  
In preliminary investigations of the indol-LPS interaction, slow establishment of the 
equilibrium is indicated (described in Chapter 2).  One additional parameter that 
must be monitored is the amount of time that the samples are incubated prior to 
introduction to the CE instrument.  Either the P or D (LPS or indol) can be varied in 
the pre-incubated samples.   
 
Frontal Analysis Capillary Electrophoresis (FACE) 
 
The greatest benefit of the FACE experimental design for determining a Kb is that it 
does not require the assumption of a 1:1 binding stoichiometry (59).  FACE is also 
known to be a robust, simple, and reliable method for the determination of a Kb (44, 
60).   Injection of large “plugs” of sample for 1-2 mins results in a plateau rather than 
the usual peaks that are produced from short 1-5 second injections.  As with any 
other CE methods, experimental parameters   (ie. buffer type and concentration, 
voltage, injection time, etc) are first optimized.  For this method to be successful, the 
mobility of the drug must differ sufficiently from the mobility of the 
complex/protein (44).   For Kb determination, pre-incubated samples of increasing 
concentration of drug and constant concentration of protein are injected together.  
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Prior to analysis of pre-incubated samples, a calibration curve of free drug plateaus 
of increasing height is built that will be used to quantify the fraction of free drug 
(61).    In the pre-incubated samples, the free drug will migrate at a different rate 
than the complex and emerge later in the electropherogram, allowing determination 
of the fraction of free drug when plateau heights are compared to the calibration. 
This data is used to plot the number of complexed molecules per molecule of protein 
as a function of the free drug concentration (62).  The resulting binding curve is fit 
using non-linear regression. 
 
Research Objectives 
 
The primary objective of this thesis is to explore the indol-LPS interaction and 
determine the most suitable CE method to elucidate a Kb at physiological pH.  A 
secondary objective is to report a preliminary Kb for the indol-LPS binding 
equilibrium. A Kb value will shed light on the strength of the binding between indol 
and LPS, corroborate the assumption that LPS is the primary receptor for indol, and 
represent a first step to determining the precise type of non-covalent interaction 
present.  Successes and failures of PI-ACE, ACE, and FACE attempts are presented 
in Chapters 2, 3 and 4, respectively. They represent a veritable roadmap for use of 
CE for the study of indol’s interactions with LPS.  From the optimized CE 
parameters outlined in this thesis, further studies of indol and its derivatives with 
other bacterial or mammalian cell wall components can continue to broaden our 
understanding of this unique AMP.  
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CHAPTER 2: PRE-INCUBATION AFFINITY CAPILLARY 
ELECTROPHORESIS 
 
Introduction 
Development of novel drugs is a pressing and world-wide issue due to the 
emergence of multidrug resistance to presently available antibiotics.  A class of 
drugs known as cationic antimicrobial peptides (CAPs) is showing promise due to 
their broad spectrum of activity and multiple modes of action resulting in decreased 
likelihood of them becoming drugs to which resistance is developed (1).  Indolicidin 
(indol) (ILPWKWPWWPWRR-NH2) is a CAP isolated from the cytoplasmic granules 
of bovine neutrophils (2). Indol is best known for its short 13-amino acid singular 
primary structure and high percentage of tryptophan (2, 3).  Despite its broad 
spectrum of antimicrobial, anticancer and antifungal activity, indol has been 
demarcated for therapeutic use due to its cytotoxic nature (3, 4).  The natural 
structure of indol, however, has represented an excellent starting point for the 
synthesis of analogues with increased bioactivity and reduced cytotoxicity (4-6).  
Still, for a derivative of indol to be useful as a therapeutic agent, more information is 
needed about its precise mechanism of action.   
Sequence, charge, size and structure all play a role in indol’s activity (7).    Many 
mechanisms of bacterial cell attack have been proposed including (but not limited 
to) membrane-thinning by disruption of headgroups, inhibition of protein and DNA 
synthesis, cell leakage via channel formation across the membrane, and 
stereospecific non-pore forming mechanisms (8-11). For pharmacological purposes, 
determination of a binding constant (Kb), which provides a ratio of bound to free 
drug, is an important starting point for drug discovery (12).  So far, a Kb for the 
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interaction of indol with its proposed corresponding receptor, lipopolysaccharide 
(LPS), has yet to be reported (13).     
Use of capillary electrophoresis (CE) for the elucidation of Kb has been steadily 
increasing and is continuing to gain popularity.  Affinity capillary electrophoresis 
(ACE) is the most widespread CE method currently in use for reporting Kb values 
with roughly 1000 publication between 2000 to 2012 (14, 15).  The ACE study design 
would require either indol or LPS to be added to the background electrolyte (BGE) 
in increasing concentrations, while using a constant concentration of the other as a 
sample with short injection.  Preliminary attempts to add indol to the BGE resulted 
in so much capillary wall adsorption (apparent from the steep baseline) as to render 
the data useless (Appendix A).  Addition of LPS to the BGE yields useable data, 
however, the molecular mass of LPS is elusive (Sigma Aldrich data sheets claim a 
mass range of 10-20 kDa), and thus requires the final Kb value to be reported in 
mg·L-1 with assumption of the LPS approximate mass used to make the conversion 
to L·mol -1.  While the conversion could allow for comparison to other literature 
values, the mass assumption introduces error (See Chapter 3).  Pre-incubation ACE 
(PI-ACE), sometimes termed capillary zone electrophoresis (CZE), involves 
combining both the protein and the drug for a set amount of time before short 
injection into the CE.  Using this study design, mixing a constant concentration of 
LPS with increasing concentrations of indol avoids the problem of capillary inner-
wall adsorption by introducing lesser quantities of indol to the system and still 
allows a Kb value to be reported in the standard L·mol -1 convention.  The Kb is 
calculated by way of changes in effective electrophoretic mobility (µeff) which 
requires a neutral marker of the electroosmotic flow (EOF) in order to compare the 
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change in electrophoretic mobility of the complex (µc) with electrophoretic mobility 
of the free protein (µf).  The following equations are used (16, 17):  
µeff =  µi - µf            (Eq. 1) 
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µeff is the effective change in electrophoretic mobility 
µi is the apparent electrophoretic mobility of the complex 
µf is the electrophoretic mobility of the free protein (this value is constant for each data set) 
Ld is the length of the capillary to the detector window (usually in cm) 
Lt is the total length of the capillary (cm) 
V is the voltage (V) 
tc is the migration time of the complex (usually in seconds) 
tm is the migration time of the marker (s) 
tf is the migration time of the free protein (s) 
 
Eq. 1 is manipulated to generate plots which serve to determine the value of Kb.  The 
different plotting forms are shown in Table 2.1.   
 
One of the setbacks of using ACE, or in this case PI-ACE, is the assumption of a 1:1 
binding stoichiometry.  The linear regression plots generated from the PI-ACE data 
can, however, give indications of different stoichiometries.  For instance, it has been 
suggested that multiple binding is most evident with the linear regression X-
reciprocal plot (19).   When two distinct trends can be seen, it is indicative of a 2:1 
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binding interaction (20).  A frontal analysis capillary electrophoresis (FACE) study 
using long injection would be most desirable to eliminate any assumptions of 1:1 
binding, however, the study herein represents a modest start to reporting an 
accurate Kb for the interaction of indol with LPS (For FACE attempts, see Chapter 4).   
 
Table 2.1: Linear regression plotting forms of binding constant (Kb).  
Method  
(synonymous names) 
Plotting Equation  
(y axis  vs x axis) 
Determination of 
Kb 
X-Reciprocal  
(Eadie plot,  
Scatchard plot) 
 
    
       
  vs       -slope 
 
Y-Reciprocal 
 
       
    
  vs               
         
 
Double-reciprocal 
(Lineweaver–Burk plot,  
Benesi–Hildebrand plot) 
 
 
    
  vs  
 
       
 
         
     
 
µeff is the change in electrophoretic mobility of the complex,         is the indol 
concentration in µM or M. Table compiled from (16-18). 
 
 
Experimental 
Materials and reagents 
Indolicidin at 97.18% purity was purchased from GL Biochem Ltd. in Shanghai, 
China. LPS isolated from E.coli (0111:B4 ) and monobasic sodium phosphate 
(NaH2PO4·H2O) were purchased from Sigma-Aldrich, Oakville, Ontario, Canada. 
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Dibasic sodium phosphate (Na2HPO4· H2O) was obtained from Caledon 
Laboratories in Georgetown, Ontario, Canada. DMSO used as EOF marker was from 
BDH Chemicals, Toronto, Ontario, Canada.  The water used to prepare the solutions 
was 18 MΩ water filtered by Barnstead™ Easypure™ RoDi.  All reagents used were 
of analytical-grade, and all reagents and BGEs were filtered through 0.45-μm 
Nylon® syringe filters (Canadian Life Science, ON, Canada). To reduce protein loss 
due to adsorption to Nylon® syringe filters, indol and LPS solutions were filtered 
with 0.45-μm Cellulose Acetate® syringe filters (Canadian Life Science, ON, 
Canada) before introduction to the CE instrument. 
BGE and Sample preparation 
A pH of 7.2 ± 0.3, resembling physiological pH, was desired for this study.   A 100 
mM phosphate buffer was prepared by mixing 100 mM dibasic sodium phosphate 
(Na2HPO4· H2O) and 100 mM monobasic sodium phosphate (NaH2PO4·H2O) to a pH 
of 7.3 on the Mettler Toledo FE20 – FiveEasy™ pH meter.  This PO42- buffer was 
stored at room temperature (~23oC).   
Stock solutions of 700 mg·L-1 LPS and 230 mg·L-1 indol were prepared directly in the 
100 mM phosphate buffer. The solutions were stored in the refrigerator (~4oC) and 
used for a maximum of 30 days.  Prior to sample preparation, all stocks and reagents 
were filtered using 0.45-µm filters prior to injection into CE.  For pre-incubated 
samples, in 500 μL sample vials, indol was diluted from  0 to 150 mg·L-1 (the 
equivalent of 0 to 78.7 (μM) and each was mixed with LPS stock diluted to a 
concentration of 50 mg·L-1 (of which the equivalent [mol·L-1] is not known). DMSO, 
used as a neutral marker, was added to the samples to produce a final concentration 
of 0.01% v/v (Table 2.2).  Each sample was gently vortexed to ensure even mixing.  
To account for incubation time, each sample was made in 15 min increments with 
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the first sample being analyzed after 2 h and subsequent samples in 15 min intervals 
thereafter.  The samples were then re-analyzed resulting in data collection at 2 ± 0.5 
h incubation, 5.5 ± 0.5 h incubation and 10 ± 0.5 h incubation.  The concentration 
ranges used were the result of previous runs indicating the need for this precise 
range to best represent the interaction. 
 
Table 2.2: Preparation of PI-ACE samples showing volume (μL) of stock LPS, 
Indol, Buffer and DMSO, and mix time for each sample. 
Indol 
Concentration 
(mg·L-1) 
230 ppm Indol 
stock (μL) 
700 ppm LPS 
stock (μL) 
(each sample is 
50mg·L-1) 
100 mM 
PO42- buffer, 
pH 7.3 (μL) 
0.1% v/v 
DMSO 
(μL) 
Mix time 
(±10 min) 
0 (DMSO only) 0 0 198 2.0 11:30 
0 0 14.3 183.7 2.0 11:45 
10 8.7 14.3 175.0 2.0 12:00 
20 17.4 14.3 166.3 2.0 12:15 
30 26.1 14.3 157.6 2.0 12:30 
40 34.8 14.3 148.9 2.0 12:45 
50 43.5 14.3 140.2 2.0 13:00 
75 65.2 14.3 118.5 2.0 13:15 
100 87.0 14.3 96.7 2.0 13:30 
150 130.4 14.3 53.3 2.0 13:45 
 
Apparatus 
PI-ACE data was collected using a Beckman Coulter ProteomeLabTM PA 800 
capillary electrophoresis instrument with ultraviolet (UV) detector set to 214 nm 
with direct absorbance. A fused-silica capillary from Polymicro Technologies, 
Phoenix, AZ, USA, of outer diameter 366.0 ± 0.2 µm, inner diameter 50.4 ± 0.2 µm, 
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48 cm effective length (to detector) and 58 cm total length was used.  A circulating 
liquid fluorocarbon coolant allowed the temperature in the capillary cartridge to be 
maintained at 25°C.  
New capillaries were conditioned with 1.0 M NaOH for 60 min at 20 psi, followed 
by 0.1 M NaOH for 30 min at 20 psi. Before each new incubation time analysis (every 
10 runs), the capillary was flushed with H2O, 0.1 M NaOH, H2O, and BGE (each for 
10 min at 20 psi of pressure).   Prior to each sample injection, the capillary was 
flushed with 0.1 M NaOH for 4.0 min, H2O for 2 min, and then BGE for 4 min (each 
at 20 psi).  Rinse steps were extensive to ensure reduction in protein adsorption to 
the uncoated capillary (18).  Normal polarity was used for all runs with voltage set 
at 20 kV for 10-15 min- enough time to observe all expected outputs. Each sample 
was injected for 5 s at 1.0 psi.  Since the benefit of automation is negated when 
samples must be prepared in a time-sensitive fashion, samples for this study were 
only conducted in single runs, with the understanding that any follow-up study 
would be conducted in triplicate at the incubation time that indicates that 
equilibrium has been reached.   
 
Results and Discussion 
 
This study was designed to examine the role played by incubation time of samples 
mixed with both indol and LPS and run under ACE conditions with the ultimate 
goal of establishing a time at which equilibrium is reached, while generating a 
preliminary Kb.  While most pre-incubation (PI) studies will attempt short 
incubation times such as 0-90 min (21, 22), preliminary attempts showed changes in 
complex and free drug mobilities when incubated for 60 min vs. 120 mins.  
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Appearance of a free indol peak that varied in size indicated a slow equilibrium (23).  
It became apparent that incubation time would be a major determinant of the final 
calculated and reported Kb value.  This is contrary to some belief that the time-frame 
of protein-binding equilibration is short (15).  The results of 2 h incubation are 
shown in Figure 2.1.  The electropherograms produced for the 5.5 and 10 h 
incubation times appear very similar to the results for 2 h incubation and it is nearly 
impossible to visually detect a change in mobility of the LPS·indol complex. The 
exception is the emergence of the free indol peak around the 40 mg·L-1 mark 
(electropherogram F of Figure 2.1), which tends to vary in size when compared over 
time (Figure 2.2).   
The visual shape and size of the free indol peak does appear to stabilize between the 
5.5 and 10 h incubation times, however, calculation of change in electrophoretic 
mobility (μeff) shows a slow continued change.  μeff was calculated by collecting the  
marker and complex peak migration times for each electropherogram to assess the 
change in mobility in the complex as the LPS binds increasingly more indol.  Linear 
regression plots of double reciprocal, Y-reciprocal, and X-reciprocal were created for 
each of the three data sets (Table 2.3).  Non-linear regression plots were disregarded 
due to low correlation coefficients (R2 ≤ 0.6). 
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Figure 2.1: Electropherograms of 50 mg·L-1LPS pre-incubated for 2h, mixed with 
DMSO (0.01 %v/v) and varying concentrations of indol: . A) 0 (DMSO only), B) 0, 
C) 5.25, D) 10.5, E) 15.7, F) 21.0, G) 26.2, H) 39.3, I) 52.5, and J) 78.7 μM  (range is the 
equivalent of 0-150 mg·L-1). Peak identities: 1) DMSO, 2) LPS/LPS-indol complex, 
3) free indol.  * is an unknown peak caused by an impurity. CE conditions are 
described in the Apparatus section.   
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Figure 2.2: Electropherograms at incubation times of 2, 5.5 and 10 hrs, of the same  
50 mg·L-1LPS sample pre-incubated with 78.7μM indol (150 mg·L-1) and 0.01 %v/v 
DMSO as neutral marker.  Peak identities: 1) DMSO, 2) LPS/LPS-indol complex, 
3) free indol. CE conditions are described in the Apparatus section. 
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Table 2.3: Compilation of regression and binding constant values for 2, 5.5 and 10 
h incubation data for the interaction of constant concentration of LPS with 
varying concentration of indol 
Incubation 
time  
(hrs ± 0.5) 
Regression 
Type 
(Reciprocal) 
Regression 
Equation 
Correlation 
(R2) 
Kb (M-1) 
X 105 
Average Kb  
(L·mol-1) X 
105 
2 
Double y = -445.53x - 365.99 0.5536 8.21 
5.22 Y y = -344.1x - 988.35 0.9950 3.48 
X y = -0.3968x - 0.0012 0.4576 3.97 
5.5 
Double y = -707.89x - 341.28 0.3689 4.82  
Y y = -325.24x - 910.82 0.9308 3.57 3.18 
X y = -0.1137x - 0.0004 0.2330 1.14  
10 
Double y = -2762x - 232.3 0.8824 0.84  
Y y = -266.24x - 1548.2 0.9836 1.71 1.11 
X y = -0.0801x - 0.0004 0.6955 0.80  
 
 
The Y-reciprocal plot returned the best R2 for each data set with all values above an 
R2 value of 0.9308 (Figure 2.3).  The Kb calculated by the regression equation 
produced by the Y-reciprocal method also most closely resembled the average of the 
three calculated Kb values.  The low R2 values of the X-reciprocal plots (Figure 2.4) 
are the best indication of a stoichiometry that does not fit 1:1 binding, yet the 
scattering of the data in the X-reciprocal plots does not show 2 or more distinct 
trends which could allow us to extract multiple binding constants (19, 20).  These 
trends could be more apparent if data for multiple runs is pooled for the optimal 
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incubation time.  The Kb values averaged for all three plotting methods for data 
collected at 2, 5.5 and 10 h (± 0.5) incubations were 5.22 x 105 L·mol-1, 3.18 x 105, and 
1.11 x 105 L·mol-1 respectively.   Figure 2.6 shows this decreasing average Kb trend 
graphically.  Considering only the three incubation times, the decrease in Kb value 
appears to occur in a rather linear fashion for the time period of 2-10 h.  Additional 
analyses were conducted with incubation times of ~3-10 h to get a bigger picture of 
the equilibrium establishment (Figure 2.7).  The added data points from these 
additional incubation times indicate that the equilibrium is reached in the 6-10 h 
range.  The supplemental data gathered also helped to support the Kb findings; 
indicating that the Kb is in the order of 105 L·mol-1.  As there has not yet been a Kb 
reported for the equilibrium interaction between indol and LPS, it is difficult to 
evaluate the reliability and comparability of these results.  The biggest obstacle for 
reporting a Kb from this data with confidence is the need to perform multiple runs at 
equilibrium, presumably for samples pre-incubated for six or more hours.     
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Figure 2.3: The Y-reciprocal plots for A) 2, B) 5.5 and C) 10 h incubation data.  
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Figure 2.4: The X-reciprocal plots for A) 2, B) 5.5 and C) 10 h incubation data. 
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Figure 2.5: The Double-reciprocal plots for A) 2, B) 5.5 and C) 10 h incubation data 
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Figure 2.6: Plot of average Kb value trend over time for data collected at 2, 5.5 and 
10 h intervals.   
 
Figure 2.7: Plot of Kb value trend over time compiled for two data sets. 
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Analyses conducted in Chapter 3 using traditional affinity CE (ACE) shows a Kb in 
the order of 106 L·mol-1, this higher value agrees with the findings in this Chapter 
due to the short incubation time utilized for the ACE method.  Using the PI-ACE 
method, long incubation times show progressively decreasing Kb values.  Using the 
traditional ACE method requires interaction and equilibration to take place on a 
much shorter timescale within the capillary. Thus, the combined findings indicate 
that the largest Kb value is achieved for lesser amounts of incubation time.  Since in 
both ACE and PI-ACE, the fraction of bound drug is estimated based on the 
mobility of the bound versus unbound species, the larger Kb value indicates a more 
“sluggish” complex that is being slowed down by more interactions with the drug 
(indol).  A hypothesized visual depiction of the interaction between indol and LPS is 
shown in Figure 2.8.  It is assumed that the receptor, LPS forms a micelle in an 
aqueous environment which mimics a cell membrane.  When indol first interacts 
with the LPS micelle, it is at the periphery of the micelle presumably using 
electrostatic interactions between the cationic amino acids of indol and the anionic 
phosphate groups of LPS.  The mobility of the complex is at this time more greatly 
affected by the location of the indol binding.  Once the electrostatic interaction binds 
indol and LPS, the hydrophobic regions of indol (namely tryptophan) interact with 
the LPS micelle to penetrate the membrane.  As this interaction occurs, the indol are 
further from the periphery of the LPS micelle and thus are not as greatly affecting 
the complex’s mobility. Finally, once indol has penetrated the micelle membrane, it 
is compromised and indol is able to bypass into the micelle, thus resulting in a less 
affected mobility of the complex.  This hypothesis would explain the progressive 
decrease in Kb value as incubation time is increased.   
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Figure 2.8: Hypothetical sequence of events for interaction of indol with an LPS 
micelle. 
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Conclusion 
 
For this study, samples containing increasing concentrations of indol and a constant 
concentration of LPS were pre-incubated for 2, 5.5 and 10 h (±0.5) and analyzed 
under the same CE conditions to provide preliminary Kb values and shed light on 
the effect of incubation time.  The results showed a clear indication of binding, 
evident by the appearance of a free indol peak once the LPS was saturated.  The 
binding was also supported by the change in electrophoretic mobility of the 
LPS/LPS-indol complex as increasing concentrations of indol were added.  For a 
preliminary data-set, a total of nine Kb values were produced: one for each of 
double, X-, and Y-reciprocal plots for each of the three incubation times assessed.  
The average of the three Kb values produced from the three regression plots was 5.22 
x 105, 3.18 x 105, and 1.11 x 105 L·mol-1 for 2, 5.5 and 10 h (± 0.5) incubations, 
respectively.  The best correlations were generated by the Y-reciprocal plots, with R2 
values of ≥ 0.9308. The double reciprocal and X-reciprocal plots had lower R2 values, 
the lowest value being of 0.2330 for the X-reciprocal plot of 5.5 hour incubation data.  
This low R2 could be indicative of multiple binding stoichiometries (19).  Collection 
of additional data supported the Kb values and showed that equilibrium is reached 
beyond six hours; therefore, a more definitive conclusion of the binding 
stoichiometries could be drawn if more replicates of the study were conducted at 
this same incubation time.  A trend of decreasing Kb is corroborated by the findings 
of Chapter 3 which give a higher preliminary Kb finding in the order of  
106 L·mol-1 when samples are not pre-incubated at all.  Furthermore, the use of 
FACE, if conducted successfully, would give a much more reliable Kb value because 
FACE analysis is not limited to 1:1 binding (24).     
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Continued work in this field would greatly benefit from determining an 
approximate molecular weight for LPS, which could be applied to the use of either 
traditional ACE or FACE where the LPS concentration could be varied.  The 
resulting Kb value could then be reported in L·mol -1 without assumptions needing to 
be made for LPS mass.  Reproduction of this study with multiple replicates could 
generate more data and perhaps a more confident Kb determination, however, the 
setup of this study is very tedious with samples needing to be made repeatedly and 
on a strict time-frame, making accurate reproduction of incubation time data 
difficult.  Determining that equilibrium is in fact established would alleviate the 
strictness currently required for this parameter, allowing for ease of automation and 
more flexibility with time at which samples are mixed.  ACE and FACE would also 
benefit the researcher with the use of instrument automation, and greatly simplify 
the study design.  A traditional ACE pilot study is discussed in Chapter 3, while 
attempts to perform FACE on the indol-LPS system is discussed in Chapter 4.   
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CHAPTER 3: TRADITIONAL AFFINITY CAPILLARY 
ELECTROPHORESIS  
 
Introduction 
Indolicidin (indol) (ILPWKWPWWPWRR-NH2) is a cationic antimicrobial peptide 
(CAP) isolated from the cytoplasmic granules of bovine neutrophils (1).  CAPs, also 
termed simply antimicrobial peptides (AMPs), are showing some promise in the 
search for new drug candidates due to their incredible spectrum of activity coupled 
with their ability to employ multiple modes of action against pathogens (2).  
Antibiotic resistance is thought to be less likely to occur when a drug uses multiple 
actions to achieve an antimicrobial result. Cytotoxicity has prevented advancement 
of indol in drug development; however, solutions have been presented. Using the 
natural structure of indol, derivatives can be created with equivalent or increased 
antimicrobial properties and reduced cytotoxicity (3-5).  Drug development is 
benefitted by the elucidation of a binding constant (Kb) which can indicate the 
fraction of free versus bound drug.  A value of Kb has not yet been published for the 
interaction of indol with its proposed receptor, lipopolysaccharide (LPS) (6). 
Comparison of elucidated Kbs to other methods of Kb determination (ie. 
spectroscopic approaches, isothermal titration calorimetry (ITC)) is recommended 
(7). These comparisons are often done within the same research group or laboratory; 
however, this is not possible for the current research. Nevertheless, a large Kb for 
this interaction would add credence to the assumption that entry into a bacterial cell 
is via LPS as receptor and would be a step towards reporting the type of non-
covalent interaction which could be elucidated by a thermodynamic study.  
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Affinity capillary electrophoresis (ACE) is one of the best known and most 
commonly used methods of Kb determination (8).  Capillary electrophoresis (CE) is 
an excellent analytical tool due to its high separation efficiency, high resolving 
power, quick analysis time, low injection volume, and ability to automate (9). The 
ACE study design is popular because it is very simple.  For our purposes, either 
indol or LPS can be added to the background electrolyte (BGE) while the other is 
injected into the capillary as a sample.  During initial research, it was found that 
addition of indol to the BGE was not a feasible study design owing to the cationic 
nature of indol which resulted in heavy adsorption to the bare fused silica inner 
capillary walls (see Appendix A).  A cationic capillary coating of hexadimethrine 
bromide and dextran (PB-DS-PB coating) was attempted to limit protein interaction 
with capillary walls, however the results were poor.  A bare fused silica capillary 
was used with special attention to rinse protocols as outlined by El-hady et al [2010] 
(10). Thus, the LPS was added in increasing concentrations to the run buffer and 
indol was injected as a sample.  All other CE parameters are kept constant while 
equilibration takes place within the capillary.  A variety of Kb values are revealed by 
producing linear regression plots from calculation of effective electrophoretic 
mobility (µeff), which is the change in electrophoretic mobility of free (µf) compared 
to complexed species (µc) (11).  The linear regression plots are the double reciprocal, 
Y-reciprocal and X-reciprocal plots.  In ACE, these plots assume a linear trend and 
1:1 binding stoichiometry (12).  A binding stoichiometry that differs from 1:1 is best 
indicated on an X-reciprocal plot, also known as a Scatchard analysis, by non-
linearity or presence of two distinct trends (11, 13).   
Studies such as this one aim to achieve a better understanding of the mechanism of 
action of a drug by evaluating the strength of its binding to its corresponding 
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receptor.  It is acknowledged that simplifying an interaction study to only include a 
drug and one receptor ignores the effect of many biological features such as 
membrane potential, pH gradients, lipid heterogeneity, the presence of membrane 
proteins and more (14).  Still, it is accepted that such studies are helpful for gleaning 
a broad overview of interaction mechanisms.  Conducting the ACE interaction study 
of indol with LPS at the physiological pH of ~7.4 was challenging due to the cationic 
nature of indol, but helps to substantiate the significance of the results.  A 
preliminary Kb range is reported from the results of this ACE study, representing 
progression to a better understanding of the interaction between the CAP indol and 
its proposed ligand, LPS. 
 
Experimental 
Materials and reagents 
Indolicidin (97.18% pure) was purchased from GL Biochem Ltd. in Shanghai, China. 
LPS isolated from E.coli (0111:B4 ) and monobasic sodium phosphate 
(NaH2PO4·H2O) were purchased from Sigma-Aldrich, Oakville, Ontario, Canada. 
Dibasic sodium phosphate (Na2HPO4· H2O) was obtained from Caledon 
Laboratories in Georgetown, Ontario, Canada. DMSO used as EOF marker was 
obtained from BDH Chemicals, Toronto, Ontario, Canada.  The water used to 
prepare the solutions was 18 MΩ water filtered by Barnstead™ Easypure™ RoDi.  
All reagents used were of analytical-grade, and all reagents and background 
electrolytes (BGEs) were filtered through 0.45-μm Nylon® syringe filters (Canadian 
Life Science, ON, Canada). To reduce protein loss due to adsorption to Nylon® 
syringe filters, indol and LPS solutions were filtered with 0.45-μm Cellulose 
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Acetate® syringe filters (Canadian Life Science, ON, Canada) before introduction to 
the CE instrument. 
 
BGE and Sample preparation 
To be applicable to physiological systems, a pH of 7.2 (+/- 0.3) was desired for this 
study.   The stock phosphate buffer was prepared by mixing 100 mM dibasic sodium 
phosphate (Na2HPO4· H2O) and 100 mM monobasic sodium phosphate 
(NaH2PO4·H2O) to a pH of 7.3 on the Mettler Toledo FE20 – FiveEasy™ pH meter.  
The resulting buffer was stored at room temperature (~23oC) and used for no more 
than 30 days.   
 Stock solutions of LPS and indol were prepared by dissolving analytically 
weighed fluffy white solid directly into the 100 mM phosphate buffer to final 
concentrations of 420 mg·L-1 and 230 mg·L-1, respectively. The solutions were stored 
in the refrigerator (~4oC) and used for a maximum of 30 days.  Prior to sample 
preparation, all stocks and reagents were filtered using 0.45-µm filters prior to 
injection into CE.  A single indol sample, of concentration 50 mg·L-1was made from 
indol stock by dilution with phosphate buffer.  DMSO, used as a neutral marker, 
was added to this sample to produce a final concentration of 0.01% v/v in a 500 μL 
sample vial.  BGE for this study consisted of concentrations of LPS from 0 to 150 
mg·L-1 dissolved in 100 mM phosphate buffer (Table 3.1).  The indol sample as well 
as the inlet and outlet vials of LPS consisting buffer were gently vortexed to ensure 
even mixing.   
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Table 3.1: Preparation of LPS containing BGE showing volumes of LPS and buffer.  
LPS concentration in BGE 
(mg·L-1) 
420 mg·L-1LPS stock (μL) 
100 mM PO42- buffer, pH 7.3 
(μL) 
0 0 1000 
25 59.5 940.5 
75 178.5 821.5 
150 357.0 643.0 
 
 
Apparatus 
Traditional ACE data was collected using a Beckman Coulter ProteomeLabTM PA 800 
capillary electrophoresis instrument with detection at 214 nm with an ultraviolet 
(UV) detector set at direct absorbance. A fused-silica capillary from Polymicro 
Technologies, Phoenix, AZ, USA, of outer diameter 366.0 ± 0.2 µm, inner diameter 
50.4 ± 0.2 µm, 48cm effective length (to detector) and 58 cm total length was used.  A 
circulating liquid fluorocarbon coolant allowed the temperature in the capillary 
cartridge to be maintained at 25°C.  
New capillaries were conditioned (each at 20 psi) with 1.0 M NaOH for 60 min, 
followed by 0.1 M NaOH for 30 min. Before the sequence was started, the capillary 
was flushed (each for 10 mins at 20 psi of pressure) with H2O, 0.1 M NaOH, H2O, 
and plain 100 mM phosphate buffer (pH 7.3).   Prior to each sample injection, the 
capillary was flushed (each at 20 psi) with 0.1 M NaOH for 4 min, H2O for 2 min, 
and then phosphate buffer for 4 min.  Extensive use of rinse steps was used to 
ensure reduction in protein adsorption to the uncoated capillary (15).  Normal 
polarity was used for all runs with voltage set at 10 kV for 20-30 min, enough time to 
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observe all expected peaks in the output electropherograms. Each sample was 
injected for 5 s at 1.0 psi.  All samples were analyzed in duplicate.   
 
Results and Discussion 
This study was designed as a pilot project to see the outcomes when traditional ACE 
is conducted using indol as the sample and LPS dissolved in the BGE.  Calculation 
of a preliminary Kb while using LPS as the varying component limits the precise 
reported Kb value to mg·L-1, due to the ambiguity behind the molar mass of LPS 
(Sigma Aldrich reports a mass range of 10-20 kDa)(16).  This approach is still 
preferred because conducting the study in reverse, by placing indol in the BGE, 
results in excessive adsorption to the inner walls of the capillary by introducing high 
concentrations of cationic indol into the system (See Appendix A).  It is also 
advantageous to keep the indol concentration constant and low to further reduce 
protein wall adsorption.  In addition, it is feasible to convert the reported Kb from 
L·mg -1to L·mol -1 by using the estimated mass range of 10 kg to 20 kg·mol-1 that is 
suggested by Sigma Aldrich.  Using this approach certainly introduces error and a 
number of questions surrounding the accuracy of the LPS mass estimation, however, 
a large Kb value can still lend support to the assumption that LPS is the probable 
receptor for indol when entering a cell.  The compiled electropherograms shown in 
Figure 3.1 were produced in duplicate and both sets of data look nearly identical.   
 
 
53 
 
 
Figure 3.1: Electropherograms of 50 mg·L-1 (26.2 μM) indol and DMSO (0.02%v/v) 
analyzed with varying concentrations of LPS added to the 100 mM phosphate 
BGE.  LPS concentrations in buffer are A) 0, B) 25, C) 75, and D) 150 mg·L-1.  Peak 
identities:  1) free indol, 2) DMSO, 3) LPS vacancy trough, 4) is the LPS/LPS-indol 
complex.  CE conditions are described in the Apparatus section.   
 
The disappearance of the indol peak immediately upon addition of just 25 mg·L-1 
LPS to the run buffer is an excellent indication of an interaction between indol and 
LPS. As more LPS is delivered to the capillary via higher concentration in the buffer, 
the complex peak grows marginally and a vacancy peak (or trough) presents itself.  
This trough indicates that LPS is being removed from the BGE and becoming part of 
a complex resulting in a lower absorbance in the region of LPS’s migration time.  
The visual trend is deceiving as the complex size seems larger for the BGE with 75 
54 
 
mg·L-1 LPS as compared to the complex when 150 mg·L-1 is present in the BGE 
(Figure 3.1 C vs. D).  The calculations of change in mobility of the indol·LPS complex 
verify that in fact the mobility of the complex is proportionally changed with 
increasing concentrations of LPS in the run buffer.  Changes in viscosity of the BGE, 
which can themselves influence changes in migration time are easily accounted for 
by multiplying effective electrophoretic mobility µeff by the ratio (Io/I), where Io is the 
current without any additives in the buffer solution and I is the current when there 
is additive in the buffer solution (17).  For these analyses, the changes in current with 
LPS in the BGE were so minor as to be deemed insignificant (Io/I ≥ 0.987). 
The data gathered from the two replicates of this study were pooled and used to 
create double reciprocal, Y-reciprocal and X-reciprocal linear regression plots 
(Figure 3.2).  The resulting Kb values are shown in Table 3.2.  As is often the case, the 
Y-reciprocal data shows the highest correlation coefficient (R2 = 0.9999), while the X-
reciprocal method has a much lower R2 value (R2 = 0.7807) (7).  This is an indication 
that the binding stoichiometry should not be assumed to be 1:1 (13).  In a follow-up 
to this pilot study, use of the recommended seven different receptor concentrations 
should be utilized, which could allow use of the X-reciprocal analysis to infer two Kb 
values, rather than just one (10, 11).   
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Figure 3.2:  (A) Y-reciprocal, (B) Double reciprocal and, (C) X-reciprocal plots of 
the ACE interaction between indol and LPS.  n=6 for each plot.  In plot A, 3 
additional points are unseen because they are exactly overlapping. 
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Use of the LPS mass range reported by Sigma-Aldrich allows the conversion of the 
Kb value from the less useful mg·L-1 to mol·L-1.  The 10-20 kDa value is suggested for 
intact bacterial LPS (16). From Table  3.2, it can be seen that converting the average 
from 0.962 mg·L-1 gives us the Kb range of 9.62- 19.2 x 106  L·mol -1.  The large Kb 
suggests that in the LPS-indol interaction equilibrium the reaction lies in the 
direction of the products (i.e., the complex is heavily favoured).  Further 
investigations of LPS molecular mass have reported 50-100 kDa when it is treated 
with sodium dodecyl sulfide (SDS) and heat (18).  The mass is even greater when 
considering the formation of micelles, which can result in aggregate masses 
upwards of 1000-4000 kDa.  The critical micelle concentration for LPS isolated from 
E.coli (0111:B4) is reported as 1.3-1.6 µM (the equivalent of 13-16 mg·L-1 -assuming 10 
kDa) and is likely to form aggregates of 43-49 molecules per micelle (19).  Selection 
of a suitable LPS mass for the unit conversion will affect the Kb outcome by several 
orders of magnitude.  From an estimated LPS mass range of 10-4000 kDa, we arrive 
at a Kb range of 9.62 x 106 to 3.85 x 109 L·mol -1.  While this is an enormous range, even 
the lowest value is indicative of an equilibrium favouring the products.   At the 
concentrations used in this study, LPS micelle formation is inevitable, and thus it is 
almost certain that we are dealing with a high and variable molecular mass (20).  
The variability is a combination of the heterogenous nature of LPS structures, and 
also the variations in aggregate formation (16).  Despite the uncertainty associated 
with LPS molecular mass, we can be certain that the mass is at minimum 10-20 kDa, 
and given the published literature suggesting aggregates of 43-49 LPS units per 
micelle, the upper mass estimate is likely closer to 980 kDa.   The result is a final Kb 
value that is at very minimum 9.62 x 106 L·mol -1, definitely in favour of the complex.   
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Table 3.2: Compilation of regression and binding constant values for linear 
regression plots of traditional ACE data for the interaction of indol with LPS 
Regression 
Type 
(Reciprocal) 
Regression 
Equation 
Correlation 
(R2) 
Kb 
(mg·L-1) 
 
Avg 
Kb 
(mg· 
L-1)  
Adjusted 
with 
10kDa 
LPS mass 
(L·mol -1) 
Adjusted 
with 
20kDa 
LPS mass 
(L·mol -1) 
Double y = -0.873x - 1.0028 0.7879 1.14 
0.962 
 
 
Y y = -0.0998x – 0.1811 0.9999 0.845 9.62 x 106 19.2 x 106 
X y = -0.9019x - 9.036 0.7807 0.902  
 
 
Initially, the baseline resolution of these findings, namely the lack of spacing 
between DMSO, the LPS trough and the indol/LPS complex seen in Figure 3.1, 
seemed unacceptable for use with Kb calculations; however, comparison to 
published electropherograms indicated otherwise (21).  Given the success of these 
pilot runs, it would definitely be advisable for the study to be reproduced with 
collection of a larger data set.  For a more confident result, upwards of seven 
concentrations of LPS in the BGE in total is advised, and conducted in triplicate with 
standard deviation reported (7, 10) .   Had the usefulness of these findings been 
recognized sooner, additional data would already have been collected, alas efforts at 
the traditional ACE study method were abandoned before this data was fully 
understood and analyzed.   
 
Conclusion 
 
A traditional ACE pilot study was implemented for investigation of the interaction 
between the AMP indol and its proposed receptor, LPS.  The indol sample 
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concentration remained constant while the concentration of LPS dissolved in BGE 
was varied.  All other CE parameters remained constant.   The results showed a clear 
indication of binding, evident by the disappearance of the free indol peak once LPS 
was present in the BGE.  A change in electrophoretic mobility of the LPS/LPS-indol 
complex peak also indicated that an interaction was taking place.  Kb values were 
produced by pooling the duplicates of each run to generate double, X-, and Y-
reciprocal plots.  The average of the three Kb values produced was 0.962 mg·L-1.  
When converted to mol· L -1 by way of a conservative LPS mass estimate of 10-20 
kDa, the result is a Kb range of 9.62- 19.2 x 106 L·mol -1.  This value is likely 
underestimated rather than overestimated given the conversion assumes a single 
LPS unit, while it is more likely in a micelle with a much larger mass.  Use of a larger 
LPS mass would only increase the estimated Kb value.  The X-reciprocal correlation 
coefficient was only 0.7807, which could be a preliminary indication that the 
stoichiometry of the binding is not 1:1 (13).  In future, the X-reciprocal plot could be 
used to elucidate two Kbs; however a larger data set would be required (11).    If 
future work is to follow the design of this study, more replicates need to be 
conducted to include upwards of seven LPS concentrations dissolved in the buffer 
and triplicates of each run to be performed.  If a frontal analysis (FACE) study can 
be successfully designed and accomplished, it would eliminate both the limitations 
of stoichiometry and the unknown LPS mass (21).  FACE is not limited to 1:1 
binding stoichiometry and it would allow the indol concentration to be varied 
instead of that of LPS.  FACE attempts for the interaction of indol and LPS are 
discussed in Chapter 4.  Results generated using the traditional ACE method with 
LPS in the run buffer corroborate the current theory that LPS is the receptor for indol 
and that the equilibrium strongly favours complexation.   
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CHAPTER 4: ROADS NOT FOLLOWED- FRONTAL ANALYSIS  
Introduction 
As with many research projects, this one began with a very specific goal of using 
frontal analysis capillary electrophoresis (FACE) to achieve a binding constant (Kb) 
for the interaction of indolicidin (indol) with lipopolysaccharide (LPS) followed by 
elucidation of the type of non-covalent interaction by way of a thermodynamic 
study.  Attempts to accomplish this objective went on for many months before a new 
approach was taken to determining a Kb (see Chapters 2 & 3).  Since space in 
journals is at a huge premium, it is simply not that common in science to report 
failures.  While understandable, it is also a shame in many respects, as the attempts 
that do not work involve as much dedicated time in the laboratory as the attempts 
that result in fruitful publications.  Without communicating these failures, what is to 
stop future researchers from wasting time on the same unproductive efforts?  What 
follows is a brief description of why the FACE method was attempted, the study 
design, unfinished results and concluding remarks. 
FACE is well regarded as a robust, simple, and reliable method for the 
determination of a Kb (1, 2).  It is also a highly attractive method because it does not 
require the assumption of a 1:1 binding stoichiometry (3).  For these reasons, the 
pursuit of a Kb was first attempted by optimizing a FA study.  The experimental 
design involves injection of large “plugs” of sample.  Rather than a standard short 
injection of 1-5 s producing peaks, FACE uses injection times upwards of 1-2 mins 
producing plateaus (Figure 4.1).  Studies commence by optimizing CE parameters 
followed by building a calibration curve of free ligand plateaus of increasing height.  
The samples that are later injected are pre-equilibrated samples of constant 
concentration of analyte and increasing concentrations of ligand.  The resulting 
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injection contains free analyte, free ligand and analyte-ligand complex.  It is 
assumed that the analyte and the complex will migrate at similar rates, but it is 
required that the ligand have a sufficiently different mobility so that it leaks out of 
the plug in a concentration proportional to the free ligand in the injected sample 
(Figure 4.2)(1).  The height of the free ligand portion of the plateau can then be 
quantified by comparison to the standard curve.  Finally, this data is used to plot the 
number of complexed ligand molecules per molecule of analyte as a function of the 
free ligand concentration (4).  The resulting binding curve is fit using non-linear 
regression. 
 
 
Figure 4.1: Representation of a short injection producing a peak (A) and a long 
injection (B) producing a plateau. 
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Figure 4.2: Theoretical representative electropherograms of a FACE study.     is the 
analyte + the analyte-ligand complex.      is the free ligand. 
 
Multiple attempts were made to allow use of FACE for elucidating a Kb for the 
interaction of indol with its proposed receptor- LPS (5).  CE condition parameters 
were optimized to the physiological pH (~7.4) in order to give the results authority 
with respect to in vivo interactions.  The following sections will summarize the 
experimental design for this study in a traditional manner, outlining the materials 
used, samples prepared, limited results, and discussion.   
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Experimental 
Materials and reagents 
All reagents used were of analytical-grade, and all reagents and background 
electrolytes (BGEs) were filtered through 0.45-μm Nylon® syringe filters (Canadian 
Life Science, ON, Canada).  At this time,  0.45-μm Cellulose Acetate® were not yet in 
use to help reduce protein loss due to adsorption, however, any protein loss would 
be equivalent and represented throughout the samples as the same stock solutions 
were used for all samples.  Indolicidin (97.18% pure) was from GL Biochem Ltd. in 
Shanghai, China and LPS isolated from E.coli (0111:B4 ) and monobasic sodium 
phosphate (NaH2PO4·H2O) were purchased from Sigma-Aldrich, Oakville, Ontario, 
Canada. Caledon Laboratories in Georgetown, Ontario, Canada supplied the dibasic 
sodium phosphate (Na2HPO4· H2O). The water used to prepare all solutions was 18 
MΩ water filtered by Barnstead™ Easypure™ RoDi.   
 
BGE and Sample preparation 
The desired pH of 7.2 (+/- 0.3) was ensured by the Mettler Toledo FE20 – FiveEasy™ 
pH meter.  A 100 mM stock phosphate buffer was prepared by mixing 100 mM 
dibasic sodium phosphate (Na2HPO4· H2O) and 100 mM monobasic sodium 
phosphate (NaH2PO4·H2O) to a pH of 7.0.  The 100 mM phosphate buffer was then 
diluted 10-fold to make a 10 mM phosphate buffer which was stored at room 
temperature (~23oC) and used for no more than 30 days.   
 LPS of 520 mg·L-1 was prepared by dissolving directly into the 10 mM 
phosphate buffer. Indol was prepared by dissolving directly into the 10 mM 
phosphate buffer (pH 7.0) to a final concentration of 640 mg·L-1. The solutions were 
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stored in the refrigerator (~4oC) and used for a maximum of 30 days.  All stocks and 
reagents were filtered using 0.45-µm Nylon® filters prior to injection into CE.  
Calibration curves were desired for both LPS and indol so that the size and shape of 
electropherograms of each could be optimized.  LPS samples were made in 
increasing concentrations from 130 mg·L-1 to 303 mg·L-1 (molar equivalent unknown).  
Indol samples were made in the range of 78 mg·L-1 to 401 mg·L-1 (equivalent of 41 
µM to 210 µM).   
 
Apparatus 
Data was collected using a Beckman Coulter ProteomeLabTM PA 800 capillary 
electrophoresis instrument with detection at 214 nm with an ultraviolet (UV) 
detector set at direct absorbance. A fused-silica capillary from Polymicro 
Technologies, Phoenix, AZ, USA, of outer diameter 366.0 ±  0.2 µm, inner diameter 
50.4 ± 0.2 µm, 40 cm effective length (to detector) and 50 cm total length was used.  
A circulating liquid fluorocarbon coolant allowed the temperature in the capillary 
cartridge to be maintained at 25 °C. Normal polarity was used for all runs with 
voltage set at 10 kV for 20-30 mins- enough time to observe all expected plateaus.   
New capillaries were conditioned (each at 20 psi) with 1.0 M NaOH for 60 min, 
followed by 0.1 M NaOH for 30 min. Before the sequence was started, the capillary 
was flushed (each for 10 mins at 20 psi of pressure) with H2O, 0.1 M NaOH, H2O, 
and plain 100 mM phosphate buffer (pH 7.3).   Prior to each sample injection, the 
capillary was flushed (each at 20 psi) with 0.1 M NaOH for 14 min, H2O for 2 min, 
and then phosphate buffer for 4 min.  Extensive use of rinse steps is always 
recommended to reduce protein adsorption to the uncoated capillary (6).  In this 
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study, introduction of a large plug of cationic indol made the need for rinsing 
increasingly important- thus the NaOH rinse was increased from the standard pre-
run rinse time of 4 mins to 14 mins.  Each sample was injected (as a rinse parameter) 
for the optimized “plateau-producing” 120 s at 1.0 psi.  Gentle vortexing ensured 
that each sample was well mixed.  All runs were produced in triplicate.  Following 
completion of reasonable calibration curves for each of indol and LPS, pre-incubated 
samples within similar concentration ranges were attempted by primarily varying 
the indol concentration and keeping the LPS concentration constant.   
 
Results and Discussion 
 
Optimizing LPS plateaus 
LPS was quite easy to optimize.  The overall neutral properties of LPS lend 
themselves to beautiful plateaus when samples are subjected to long injection.  
Figure 4.3 shows plateaus of increasing height generated from the LPS concentration 
range of 130 mg·L-1 to 303 mg·L-1.  Triplicates of these samples were run, each having 
very similar appearances. The increasing plateau height is evident with increasing 
concentrations of LPS.  The purpose of the LPS plateaus is primarily to observe the 
shape and size of the resulting electropherograms for optimization and was 
conducted successfully. 
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Figure 4.3: Representative electropherograms of samples of LPS mixed to varying 
concentration in 10 mM phosphate buffer (pH 7.0).  LPS concentrations were A) 
130, B) 173, C) 217, D) 260, and E) 303 mg·L-1.  CE conditions are described in the 
Apparatus section. 
 
Indolicidin Standard Curve 
After reproducible injection parameters were determined for LPS, an indol standard 
curve was then attempted using the same parameters.  The study as a whole 
requires development of an indol standard curve so that the LPS can remain 
constant and indol can be varied when pre-incubation and plug injection take place.  
This is necessary because indol is the drug and its free fraction will migrate at a 
significantly different rate than the LPS/LPS-indol fraction due to size and charge.  It 
is then also helpful that the molecular mass of indol is known (1.9063 kg·mol -1) 
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while LPS’s is not (Sigma Aldrich reports a mass range of 10-20 kg·mol -1) (7).  
Unfortunately, a standard curve for indol is harder to build.  The cationic nature of 
indol causes adsorption to the silanol groups of the inner wall of the capillary, 
especially to surface defects (8). The result is plateaus with a less desirable shape 
that strays from that of an ordinary plateau (Figure 4.4).  Reducing the pH to 5 or 6 
would alleviate this issue, but would result in findings that are not applicable to 
physiological systems.  Capillary coatings were also briefly attempted (cationic PB-
DS-PB and neutral CHO carbohydrate coating), however, results continued to be 
unfavourable and a bare fused silica capillary was reinstated.  Best efforts were 
made to build a standard curve for indol at the physiological pH.  All runs were 
performed in triplicate, with each replicate appearing very similar.  As indol 
concentration is increased, more cationic peptides are available for adsorption, and a 
peak is seen to appear within the indol plateaus (most visible on Figure 4.4 C & D).  
It is assumed that this peak is generated by large volumes of indol being released 
from their attractions to the inner walls and migrating to the detector in large 
groups.  After many attempts to better optimize the BGE solution and its 
concentration, voltage, ligand concentration, injection time and pressure, to no avail, 
it was finally decided to move on with the calibration curve pictured in Figure 4.4  
Moving forward would at least give a feel for whether FACE could be a viable 
method after all.   
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Figure 4.4: Representative electropherograms of varying concentrations of indol in 
10 mM phosphate buffer (pH 7.0).  Indol concentrations were A) 79, B) 175, C) 217, 
D) 300 mg·L-1.  CE conditions are described in the Apparatus section. 
 
Attempting FACE 
Once an indol standard curve was built, we could proceed to combine our drug with 
our receptor, in this case indol with LPS.  The concentration of indol is varied while 
that of LPS is kept constant.  Incubation time of the samples could play an important 
role in the final calculated Kb value. To get an idea of the effects of incubation time, 
triplicate runs of each sample are conducted consecutively, resulting in incubation 
time of approximately 1 hr, 2.5 hrs and 4hrs.  The goal is to assess the changes that 
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occur at these incubation times and to see if and when the equilibrium seems to be 
reached.  Since the concentration ranges used for both the free indol and LPS were in 
the range of 50-400 mg·L-1, the first set of pre-incubated samples were made with a 
constant 250 mg·L-1 of LPS and 100, 175 and 250 mg·L-1 indol (Figure 4.5). 
 
As can be seen by Figure 4.5, there is a shoulder on each of the electropherograms, 
which does seem to indicate an increase in the proportion of free indol.  The 
triplicates of each sample were very similar in migration time and overall plateau 
shape indicating that equilibrium is in fact already established at 1 h and little 
change is experienced thereafter.  Based on the shape of these preliminary outputs, 
the next samples were run with lower concentrations in an attempt to reduce the 
overall plateau height (Figure 4.6).   
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Figure 4.5: First electropherograms from the pre-incubation of varying 
concentrations of indol with constant 250 mg·L-1 concentration of LPS. Indol 
concentrations were A) 100, B) 175, and C) 250 mg·L-1.     is the LPS/LPS-indol 
complex, and * is the free indol.  CE conditions are described in the Apparatus 
section. Incubation times varied from 1-4 hours.   
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Figure 4.6: Pre-incubation of varying concentrations of indol with constant 150 
mg·L-1 concentration of LPS. Indol concentrations were A) 50, B) 87.5, and C) 125 
mg·L-1.     is the LPS/LPS-indol complex, and * is the free indol.  CE conditions are 
described in the Apparatus section. Incubation times varied from 1-4 hours.   
 
The trends of increasing free indol fraction are consistent at both the higher and the 
lower concentration ranges as seen in Figures 4.5 and 4.6, respectively.  To 
definitively indicate the identity of the shoulder, spiking was conducted where 350 
mg·L-1 of indol was mixed with just 130 mg·L-1 LPS.  The outcome was a very sharp 
increase in the height of the indol portion of the resulting plateau in the region 
where it was expected (on the righter-most side of the plateau) (Figure 4.7).  With a 
definitive trend identified and corroboration of the region of the plateau that 
represents the free indol fraction, consideration was then given to the concentrations 
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that should ultimately be used for further analysis.  Upon overlaying the pre-
incubated electropherograms with those of free indol and LPS of similar 
concentrations, it becomes apparent that there is an absorbance issue (Figure 4.8).  
The plateau heights produced from mixing the LPS and the indol dwarf the plateaus 
of both free indol and LPS of similar concentrations produced under the same CE 
conditions, but on separate days.  The free indol and LPS analyses were performed 
four days prior to the analysis of mixed indol/LPS.   In order to be able to use the 
indol calibration curve for interpolation, the height of the resulting indol fraction 
needs to be within the calibration range. 
In the second round of FACE attempts (Figure 4.6), the concentrations of indol that 
were mixed with LPS ≤ to 125 mg·L-1 and yet based on the indol calibration curve, 
the fraction of free indol is outside the range of the reference standards which were 
in the range of 79 mg·L-1 to 324 mg·L-1.  An explanation for the sudden absorbance 
increase is not forthcoming.  It could only be assumed that an unknown change 
occurred to the instrument between data collections.  
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Figure 4.7: Pre-incubation of 130 mg·L-1 LPS with 350 mg·L-1 indol to identify the 
righter-most region of the plateau as free indol.       is the LPS/LPS-indol complex, 
and * is the free indol.  CE conditions are described in the Apparatus section. 
Incubation times varied from 1-4 hours.   
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Figure 4.8: Overlay of the 150 mg·L-1 LPS mixed with 50 mg·L-1 indol 
electropherogram with free LPS and indol electropherograms (130 mg·L-1and 79 
mg·L-1, respectively).  CE conditions are described in the Apparatus section. The x 
and y axis were altered for ease of comparison.   
 
Conclusion 
 
The electropherograms produced from mixing LPS and indol were considered 
unusable because the shoulder that we have now identified as the free indol fraction 
was not recognized.  Once the free indol portion of the plateaus was identified and 
the data was further investigated, it was discovered that mixing indol and LPS 
somehow increased absorbance by the complex and the values for free indol fall 
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outside the range of the calibration curve.   This work was set aside before 
completion due to adsorption troubles faced when building the indol standard 
curve, a misunderstanding of the mixed sample plateau outputs and finally a 
mismatch of absorbance readings.  If this work is to be attempted again in the future, 
optimizing a shorter injection time (ie., 30-60s) might result in less adsorption when 
building the indol calibration curve. Most importantly, to save precious time, run 
indol by itself and then immediately, within the same sequence, compare the 
absorbance readings of the free indol analysis with absorbance readings of indol 
mixed with LPS.  With any luck, the absorbance changes that were seen in the 
results herein were from an unidentified change to the instrument and will not 
cause similar confusion in future research.     
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CHAPTER 5: CONCLUSION  
 
Motivation for novel drug discovery is global and the growing crisis in antibiotics is 
being broadcast on mainstream news networks regularly.  The introduction of a 
novel antibiotic could allow us a fresh start: a drug that is used in appropriate doses, 
and for appropriate applications.  The process of drug development is long and 
arduous and requires many different steps in research development. Each and every 
drug-related study contributes to the body of knowledge that could expedite the 
process of getting the latest discovery to market.  Cationic antimicrobial peptides 
(CAPs) have been the focus of extensive research due to their broad potential for 
use.  While an astounding break-through is still to come, adding to the knowledge 
and tools available for drug study could contribute to that much needed break-
through.  The CAP indolicidin (indol) is unlikely to be the precise revolutionary 
drug that helps to curb antibiotic resistance; however, the methods that are 
developed for its study can further be applied to other possibilities and gets us 
closer to a solution to the ever growing problem of antibiotic resistance.  The 
variations of indol that have been developed are excellent candidates for continued 
study (1-3).   The methods for studying indol with capillary electrophoresis (CE) 
optimized within this thesis are very likely applicable to studying those mutants.   
 
Determining a preliminary binding constant (Kb) between a drug and its receptor is 
an important step in beginning drug discovery (4).  This thesis can be viewed as a 
road-map for how best to study the indol-lipopolysaccharide (LPS) interaction.  
Frontal Analysis (FA) CE was the least optimized method reviewed, however it has 
the greatest promise when it comes to elucidating a Kb that can indicate multiple 
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binding.  Research using the FA study design was originally halted due to the 
perception of poor results.  That perception has since been reconsidered, and the 
prospect of continuing research with FA parameters is optimistic.  For a researcher 
attempting to continue this work, the optimized conditions for producing well-
resolved electropherograms are provided with suggestions for improvement in 
Chapter 4.   
Affinity CE (ACE) and pre-incubation ACE (PI-ACE) were also discussed within this 
thesis in Chapters 3 and 2, respectively.   For the traditional ACE method, a Kb range 
was determined as 9.62- 19.2 x 106 L·mol -1.  The range is limited by the assumption of 
the LPS molecular mass, which was assumed to be 10-20 kDa (5).  Determining a 
precise Kb while adding LPS as a run buffer additive is going to introduce error due 
to the ambiguity of the LPS mass, however, given that the LPS used (from E.coli 
0111:B4- Sigma Aldrich) forms aggregates of 43-49 molecules per micelle, we can be 
quite confident that the reported Kb range of 9.62- 19.2 x 106 L·mol -1 is 
underestimated rather than overestimated (6).  Replication of this work with more 
LPS concentrations in the buffer and conducted in triplicate will greatly increase the 
confidence in the final reported Kb.   
For the PI-ACE method, Kb values were produced for each of three incubation times 
that were investigated from the average of the three regression plots (double, X-, 
and Y-reciprocals).   The values obtained were 5.22 x 105, 3.18 x 105, and 1.11 x 105 
L·mol -1 for 2, 5.5 and 10 h (± 0.5) incubations, respectively.  A steady decrease in Kb 
was seen over the course of the incubation times studied and further investigation 
indicated that equilibrium appears to be established after approximately six hours of 
incubation.  The values reported from the PI-ACE method suffer from very limited 
quantities of data.  While the study design has been optimized and could be 
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reproduced in triplicate to give more confident results, the time required to analyze 
pre-incubated samples in a time-sensitive manner is excessive and this method 
would not be recommended as the most suitable option for Kb determination.   
From the work that has been presented here, it is the author’s hope that research will 
continue and result in publication of a confident Kb by using one or more of ACE as 
discussed in Chapter 3, PI-ACE as discussed in Chapter 2, or FACE as discussed in 
Chapter 4.  These study designs can then be replicated to elucidate a Kb for the indol 
derivative known as Δ 4,5 which has shown heightened antimicrobial action and 
reduced cytotoxicity (1).  Furthermore, LPS which has been used as the assumed 
Gram-negative cell receptor could then be replaced with sphingomyelin. 
Sphingomyelins are sphingolipids present in the plasma membrane of animal cells 
(7). They are thought to be the indol receptor in animal cells and a Kb between them 
could shed light on the mechanism of action and be helpful for further reducing 
cytotoxicity of indol mutants.  Preliminary findings presented in this thesis 
corroborate the current belief that when indol interacts with a Gram-negative 
bacterial cell, LPS is its primary receptor.   
 
The bigger picture 
 
While antibiotic use and misuse is presenting a global health concern, is it also an 
environmental concern (8).  Antibiotic resistance genes (ARGs), most commonly 
thought to be found in hospital settings, are being found in increasing quantities in 
the environment as well (9).  Urban and agricultural environments are showing 
significant levels of ARGs in both the influent and effluent of wastewater and 
drinking water treatment plants (10-12).  The presence of both ARGs and antibiotics 
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in our ecosystems is detrimental to the species within them.  Many studies have 
endeavoured to quantify the extent of the hormones and drugs in our wastewater 
and the impact of the presence of those drugs (13, 14).  For years, we have used a 
variety of over-the counter and prescription drugs for a variety of health-related 
reasons, not realizing their effect on a wide range of organisms in the environment 
and the resounding effect on environmental health (15).  Misuse of antibiotics has 
led us to a reduction in ecosystem health and to the health crisis that is antibiotic 
resistance.  Insufficient regulations and control surrounding antibiotics could 
literally mean a return to the pre-antibiotic era for many types of infections (16).  The 
successful development of a new class of antibiotics at a time when we better 
understand the breadth of the mistakes we have made could allow us a second 
chance to get it right.  While the need to develop new treatments is becoming more 
critical each day, the delay is exacerbating the importance of correctly managing any 
new discoveries so that we don’t end up on this very same road just a decade or two 
from now.   
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APPENDIX A:  AFFINITY CE WITH LPS AS THE SAMPLE AND 
INDOL DISSOLVED IN THE BACKGROUND ELECTROLYTE 
 
 
 
 
 
 
 
 
 
 
 
Figure A1: Representative electropherograms from the traditional ACE attempts 
with indol dissolved in the background electrolyte.  Sample was a constant 
concentration of 50 mg·L-1 LPS dissolved in 100 mM phosphate buffer (pH 7.3).  
Separation buffer was 100mM phosphate buffer (pH 7.3) with increasing 
concentrations of indol.  Indol concentrations dissolved in run buffer were A) 0, 
B) 10, C) 20, and D) 50 mg·L-1.     is the DMSO neutral marker which was verified 
by spiking, and      is the LPS/LPS-indol complex.    The arrow indicates the time 
when a free indol sample peak would normally be present and shows where 
adsorption is very clearly occurring.  Samples were injected for 5 s duration at 1.0 
psi, with 10 kV separation voltage, normal polarity, detection at 214 nm, with 10 
mM PO42- (pH 7.3) as run buffer.   
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APPENDIX B: SOLID PHASE PEPTIDE SYNTHESIS OF 
INDOLICIDIN 
 
Introduction 
 
The antimicrobial peptide (AMP) indolicidin (indol) is a short sequence made of just 
13 amino acids.  Despite the small number of amino acids that make up its structure, 
it is still an expensive item to order in its purified form. Purchased from GenWay 
Biotech in San Diego, California, a 20 mg vial of >95% pure indol costs upwards of 
$500.00.    In addition, the purified product can take 3-6 weeks to arrive to the lab for 
use.  These factors render it advantageous to synthesize peptide sequences in-house.  
While an in-house synthesized indolicidin sample was not used for the research 
conducted herein, the process of producing indolicidin was started in the hopes of 
providing an ample supply for future research.  What follows is a very brief 
overview of the steps involved to accomplish basic peptide synthesis.  Subsequently, 
experimental use of the Tribute Peptide Synthesizer by Protein Technologies Inc, 
and the steps remaining to complete cleaving the peptide from the resin and of its 
side chain protecting groups and purification are presented.   
 
Peptide Synthesis 
Interest in peptide synthesis has been largely driven by the desire to discover novel 
drugs for therapeutic use.  Synthesis of peptides by manipulation of amino acid 
sequences has allowed researchers to alter and improve the therapeutic properties of 
known peptides (1).  Structures of natural products present an excellent starting 
point for synthesis of peptide sequences and can be improved upon by changes in 
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specific amino acids in a series.  It is then also possible for non-natural amino acids 
to be used to further expand synthetic options (2).   
The synthesis of peptides was revolutionized in 1963 by Robert Bruce Merrifield 
with the release of his journal article publication “Solid Phase Peptide Synthesis. I. 
The Synthesis of a Tetrapeptide”(3).  At the time, liquid phase peptide synthesis was 
the method of choice and allowed for the easy synthesis of most small peptides.  
Merrifield’s innovation of the solid phase method of peptide synthesis (SPPS) was 
able to overcome some of the challenges of solubility and purification problems 
faced when attempting larger peptide sequences.  SPPS has since grown to become 
the preferred method, allowing for rapid synthesis of long peptides, automation, 
and a large capacity (4).   
Peptide synthesis, in its simplest form, involves the joining of amino acids via 
peptide bonds.  In SPPS, resins are used which provide a solid starting point, or 
scaffold on which the peptide sequence is built.  Whether liquid or solid phase, the 
process consists of four general steps: 1) N protection, 2) OH activation, 3) 
Deprotection, and 4) Coupling.  Each of these steps will be examined with respect to 
coupling of the first two amino acids of the indol sequence (Figure B1).  In nature, 
protein synthesis is accomplished from the N terminus to the C terminus and thus 
the typical convention for writing an AA sequence is from N  C.  In SPPS, the 
amino acids are coupled in reverse order, from the C terminus to the N terminus.  In 
this particular scenario, the first amino acid to be added to the resin will therefore be 
arginine (R), followed by another arginine (R), and then tryptophan (W) and so on.  
To understand the overall process of SPPS, it is important to first grasp the concepts 
of N protection and OH activation. 
 
88 
 
 
Figure B1: Indolicidin amino acid sequence depicted from N to C terminus and C 
to N terminus. 
 
N protection 
 
Without the use of N protection, several combinations of coupling are possible 
between two amino acids as multiple nitrogen groups would be available to react.  
By using the steps of 1) N protection and 2) OH activation, the direction of the 
reaction can be greatly controlled resulting in a higher percentage of the desired 
peptide sequence.   Reaction 1 depicts protection of one nitrogen on arginine with a 
very common protecting group, fluorenylmethyloxycarbonyl chloride (Fmoc).   
 
 
Reaction 1: Arginine undergoing Fmoc protection. 
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The N protection step is vital to a controlled synthesis and ensures that unwanted 
reactions are less likely to take place. In current practice, however, the amino acid 
residues that are used for peptide synthesis come in prepared vials in protected 
form.  Not only are the nitrogens protected, but also any other reactive side chain 
groups of concern.  As a result, the action of protecting no longer needs to be 
conducted in the lab; nevertheless a proper understanding of the process is still 
required to ensure correct automation of the instrument.   Further control of the 
desired coupling is ensured by OH activation.   
 
OH activation 
 
OH activation is an additional step that ensures a controlled synthesis. It involves 
use of an activating agent, sometimes referred to as a coupling agent.  Two of the 
most commonly used coupling reagents are: 2 - (1H - Benzotriazole - 1 - yl) - 1,1,3,3 - 
tetramethyluronium hexafluorophosphate and 2 - (6 - Chloro - 1H - benzotriazole - 1 
- yl) - 1,1,3,3 - tetramethylaminium hexafluorophosphate (HCTU).  In preparation 
for activation, the arginine is first subjected to N-methylmorpholine (NMM), an 
organic base that removes the acidic hydrogen from the carboxylic acid and, in this 
case, prepares it for a reaction with HCTU (Reaction 2).  Just as the prepared amino 
acid vials come ready to use with N-protection, the vials also include the activating 
agent HCTU.  The activating agent is used on the amino acid to be coupled which is 
itself Fmoc protected.   
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Reaction 2: Fmoc protected arginine amino acid that has been treated with the 
organic base NMM undergoing activation by the coupling agent HCTU. 
 
Using the principles of 1) N protection and 2) OH activation, we can achieve a 
controlled synthesis by continuing with the steps of 3) Deprotection and 4) 
Coupling. The use of resin will be introduced to explain the addition of the first two 
arginine (R) residues to the growing indol peptide chain.   
 
Peptide chain elongation  
 
SPPS begins by coupling the first amino acid in the peptide series to a solid resin.  
There are many resin types available for use, for our purposes, rink amide resin was 
used which would yield an amidated C-terminus after resin cleavage.  The addition 
of the first amino acid to the resin is similar to the coupling step of peptide 
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synthesis.  Addition of protected and activated arginine forms a bond between the 
nitrogen of the rink amide resin and the carbon of the carboxylic acid (Reaction 3). 
 
 
Reaction 3: Rink amide resin coupling with HCTU activated, Fmoc protected 
arginine (R).   
  
Following coupling of arginine to the resin, we can proceed with chain elongation 
by deprotection and coupling to the next amino acid (Reaction 4).  Deprotection is 
conducted on the amino acid that is already linked to the resin by use of piperidine 
which removes the Fmoc protecting group.  Coupling will proceed in a very 
controlled manner because the arginine to be added to the reaction is itself Fmoc 
protected and HCTU activated.  As such, the nucleophile and electrophile have been 
predetermined by use of appropriate protection and activation moieties.   
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Reaction 4: Arginine amino acid coupling with Fmoc protected and HCTU 
activated Arginine.  The result is two arginine residues in sequence attached to 
the rink amide resin.  The second arginine of the sequence is still Fmoc protected.   
 
To continue peptide chain growth, we would continue to deprotect the already 
coupled amino acid and couple to the next amino acid which would itself be Fmoc 
protected and HCTU activated.  This series of steps is repeated until all 13 amino 
acids of the indol peptide have been coupled. 
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Experimental 
 
Equipment and Reagents 
The AMP indol (ILPWKWPWWPWRR-NH2) was synthesized by SPPS using the 
Tribute®peptide synthesizer by Protein Technologies, Inc.  The synthesis was 
conducted on a 0.1 mmol scale, and used amino acids in the standard five-fold 
excess.  Prepared and sealed vials of Fmoc protected, HCTU containing amino acids 
were obtained from Protein Technologies.  Vials in the 0.5 mmol scale were used 
primarily.  When necessary, 1.5 mmol and 2.5 mmol vials were opened and divided 
into 0.5 mmol fractions.    The necessary quantities of reagents were determined by 
adding 50% to suggested volumes proposed by the instrument’s “bottle 
calculations”.  Reagents were placed in designated Tribute® bottles (Table B1).  Rink 
amide resin was obtained from Advanced Chemtech, Louisville, United States.  
Dimethylformamide (DMF) and piperidine were obtained from Sigma-Aldrich, 
Oakville, Ontario Canada.   A  20%v/v piperidine was prepared by mixing with 
DMF.  The organic base NMM was made in 0.4 M by mixing with DMF.   
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Table B1: List of Tribute® bottles, their contents, volume and use during 
Indolicidin synthesis. 
Bottle # Reagent Volume (mL) Use 
①, ② Dimethylformamide (DMF) 600 Washing, swelling 
resin 
③ 20%v/v piperidine/DMF 150 Fmoc deprotection 
④ 0.4M N-methylmorpholine 
(NMM)/DMF 
125 Base used during 
activation 
⑤ Dichloromethane (DCM) 0 Cleaving, cleaning 
instrument 
 
System Automation 
Bottles were pressurized with N2 to 9 psi and valves to 45 psi.  The Tribute® was 
loaded with prepared amino acid vials in the C  N order.  A single synthesis in 
one reaction vessel was programmed with the first amino acid to be added directly 
to the resin being assigned the “standard swell” program.  The remaining 12 amino 
acid vials used the “standard coupling” program. Following completion of the 
amino acid coupling, a “standard deprotect and dry” program was used on the 
peptide chain to leave the terminal amino acid deprotected.  The resulting peptide, 
still attached to the resin, was transferred to a small, well-sealed vial and placed in 
the freezer for storage until cleaving from the resin, purification and identification 
can be completed.   
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Achieving a purified indolicidin product 
Although the Tribute® can cleave the peptide from the resin directly on the 
instrument using the dichloromethane (DCM) in bottle  ⑤, the process is quite foul 
smelling and thus is preferably done in a fume hood with a cleavage mixture (82.5% 
trifluoroacetic acid (TFA); 5% thioanisole; 5% phenol; 5% water; 2.5% 
ethanedithiol)(1) .  Cleaving takes approximately 8 h at room temperature (~23oC) 
and yields the desired amidated C-terminus.   
Purification and extraction remain before acquiring the final synthesized peptide.  
The TFA and DCM are removed by rotary evaporation and the peptide is then 
redissolved in water.  Extraction into diethyl ether removes some impurities. 
Filtered samples are then injected into an HPLC and “the biggest peak” is manually 
collected.  The HPLC is run with helium sparged filtered water (0.1% TFA)/HPLC-
grade acetonitrile (0.05% TFA) gradient (1). In the past, lyophilization at Agriculture 
Canada was used to dry the final peptide.  Verification of the final peptide sequence, 
to ensure that indolicidin was indeed synthesized, is best conducted by mass 
spectrometry.   
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